Free Trial

T2 Biosystems Q2 2024 Earnings Report

T2 Biosystems logo
$0.14 +0.01 (+8.00%)
As of 03/3/2025 03:57 PM Eastern

T2 Biosystems EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.97
Beat/Miss
Beat by +$0.31
One Year Ago EPS
N/A

T2 Biosystems Revenue Results

Actual Revenue
$1.95 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

T2 Biosystems Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

T2 Biosystems Earnings Headlines

T2 Biosystems initiates major layoffs, seeks asset sale
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
T2 Biosystems to be delisted from Nasdaq
See More T2 Biosystems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like T2 Biosystems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on T2 Biosystems and other key companies, straight to your email.

About T2 Biosystems

T2 Biosystems (NASDAQ:TTOO), an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

View T2 Biosystems Profile

More Earnings Resources from MarketBeat